Clinical Epidemiology (Dec 2021)
Healthcare Utilization and Comorbidity in Chronic Lymphocytic Leukemia
Abstract
Emelie C Rotbain,1– 5 Klaus Rostgaard,3,5 Michael A Andersen,2,3 Caspar Da Cunha-Bang,2 Carsten U Niemann,2 Henrik Frederiksen,1,4,6 Henrik Hjalgrim2,3,5,7 1Department of Hematology, Odense University Hospital, Odense, Denmark; 2Department of Hematology, Rigshospitalet, Denmark; 3Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark; 4Department of Clinical Research, University of Southern Denmark, Odense, Denmark; 5Danish Cancer Society Research Center, Hematology Research Group, Copenhagen, Denmark; 6Academy of Geriatric Cancer Research (AGECARE), Odense University Hospital, Odense, Denmark; 7Department of Clinical Medicine, Copenhagen University, Copenhagen, DenmarkCorrespondence: Emelie C RotbainDepartment of Hematology, Odense University Hospital, Kløvervænget 6, Odense, DK-5000, DenmarkTel +45 5369 0201Email [email protected]: Age-related comorbidity is highly prevalent in chronic lymphocytic leukemia (CLL). The purpose of this study was to provide information on current patterns of healthcare utilization in CLL.Patients and Methods: We used data from Danish nation-wide registers to study healthcare utilization the year before and the year after CLL diagnosis and in relation to first-line treatment. Patients diagnosed with CLL between 1997 and 2018 were included and stratified on number of comorbidities, presence of specific comorbidities, and fitness status, respectively. Healthcare utilization was studied in terms of hospital admissions, in-hospital bed days, out-patient visits, emergency room visits, and prescription drugs. Odds ratios with 95% confidence intervals were calculated using multivariable logistic regression analyses adjusting for age, sex, and calendar year.Results: The study comprised 9170 patients with CLL with a median age of 71 years, of whom 35% had ≥ 1 comorbidity. Healthcare utilization increased markedly upon CLL diagnosis both in patients with and without comorbidities. During the year after CLL diagnosis, 39% were hospitalized, 16% visited an emergency room, 88% visited an out-patient clinic, and 93% received prescription drugs. Both individual comorbidities and the total number of comorbidities were associated with increased healthcare utilization of all types, except for contacts to hematological departments.Conclusion: Our results suggest that CLL diagnosis may unveil incipient diseases and aggravate comorbidities and thereby have considerably wider health implications than those directly related to CLL. These findings may be used by clinicians and decisions makers to guide planning of multidisciplinary care for cancer patients.Keywords: chronic lymphocytic leukemia, hematology, epidemiology, real-world data
